IHCP bulletin

INDIANA HEALTH COVERAGE PROGRAMS BT202198 NOVEMBER 4, 2021

IHCP updates PA criteria for HCPCS code Q2041 (Yescarta)

As published in *Indiana Health Coverage Programs (IHCP) Bulletin* <u>BT201811</u>, the IHCP covers axicabtagene ciloleucel (Yescarta) with prior authorization (PA). Yescarta is billed using Healthcare Common Procedure Coding System (HCPCS) code Q2041 – *Axicabtagene ciloleucel, up to 200 million autologous anti-CD19 CAR T cells, including leukapheresis and dose preparation procedures, per infusion.* As published in *IHCP Bulletin* <u>BT201812</u>, Yescarta is carved out from managed care, which means that claims and PA are processed through the fee-for-service (FFS) delivery system for all members.

PA criteria for Yescarta, published in <u>BT202110</u>, have been updated to include the diagnosis of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Effective for dates of service on or after **July 1, 2021**, the following medical necessity criteria must be met:

 Member has not previously received the specified chimeric antigen receptor T-cell (CAR-T) treatment



- Member will be administered the specified CAR-T treatment:
 - At a facility that is Risk Evaluation and Mitigation Strategy (REMS) Program-certified for the specified CAR-T treatment
 - By healthcare providers that have successfully completed the specified CAR-T REMS Program Knowledge Assessment
- Member is at least 18 years of age with one of the following diagnoses:
 - Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
 - Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy:
 - Including any of the following:
 - ⇒ Diffuse large B-cell lymphoma (DLBCL) not otherwise specified
 - ⇒ Primary mediastinal large B-cell lymphoma
 - \Rightarrow High grade B-cell lymphoma
 - \Rightarrow DLBCL arising from follicular lymphoma
 - And does not have a diagnosis of primary central nervous system lymphoma

Questions about PA for all IHCP enrolled members, specific to procedure code Q2041 (Yescarta), should be directed to Gainwell Technologies at 800-457-4584, option 7.

Individual managed care entities (MCEs) establish and publish reimbursement, PA, and billing criteria within the managed care delivery system. Questions about managed care billing and PA for procedures other than, but related to, procedure code Q2041 (Yescarta) should be directed to the MCE with which the member is enrolled.



Coverage information for procedure code Q2041 is reflected in the Professional Fee Schedule, accessible from the IHCP Fee Schedules page at in.gov/medicaid/providers.

QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 800-457-4584.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the Bulletins page of the IHCP provider website at in.gov/medicaid/providers.

TO PRINT

A printer-friendly version of this publication, in black and white and without photos, is available for your convenience.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the IHCP provider website at in.gov/medicaid/providers.

